Differential structural responses of small resistance vessels to antihypertensive therapy.
نویسندگان
چکیده
منابع مشابه
Differential structural responses of small resistance vessels to antihypertensive therapy.
Regression of left ventricular hypertrophy after control of blood pressure has been documented with some antihypertensive agents but not with others. To determine whether similar differences in regression of wall thickening also occur in resistance vessels during treatment, matched groups of spontaneously hypertensive rats (SHR) were treated for 12 weeks with either hydralazine (H) or captopril...
متن کاملHYPERTENSION Differential structural responses of small resistance vessels to antihypertensive therapy
Regression of left ventricular hypertrophy after control of blood pressure has been documented with some antihypertensive agents but not with others. To determine whether similar differences in regression of wall thickening also occur in resistance vessels during treatment, matched groups of spontaneously hypertensive rats (SHR) were treated for 12 weeks with either hydralazine (H) or captopril...
متن کاملDifferential responses of two Iranian rice cultivars to arsenite toxicity
Arsenic (As) is a toxic metalloid which is usually found in rice fields as a contamination and has negative effects on the plant growth and reduces the crop yield. Similar to heavy metals, the deleterious effects of As may be due to, at least in part, the amount of absorbed As and disturbance of the plant water status. I...
متن کاملNocebo responses to antihypertensive medications.
Apatient was seen in consultation for intolerance to multiple antihypertensive medications. She presented a list of her experiences, which is summarized in the Table. Although the cough she experienced while taking angiotensinconverting enzyme inhibitors was a typical side effect of this drug class and consistent on rechallenge, this was not the case with her other reported medication reactions...
متن کاملResistance to HER2-targeted therapy
Production and approval of trastuzumab (Herceptin®) for the treatment of metastatic breast cancer (MBC) was a millstone in antibody-based targeted therapy in the cancer treatment. However, despite the early success in the clinical trials, trastuzumab failed to appreciate the initial attraction due to development of resistance to the drug. The majority of patients who benefit from the drug...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Circulation
سال: 1987
ISSN: 0009-7322,1524-4539
DOI: 10.1161/01.cir.75.3.618